In the 1,137-patient Phase III INTerpath-001 study, Moderna and Merck’s personalized mRNA neoantigen vaccine intismeran autogene (V940/mRNA-4157) plus pembrolizumab cut the risk of recurrence or death by 42% versus pembrolizumab alone in resected stage IIB-IV melanoma. Detailed data released ahead of an ESMO presentation showed a recurrence-free survival hazard ratio of 0.58 at a median 24.6 months’ follow-up, while overall survival remains immature.

Why It Matters To Oncology

• This is among the clearest late-stage validations yet for a personalized cancer vaccine approach in solid tumors.

• The regimen also reduced the risk of distant metastasis or death by 38% (HR 0.62; p=0.002), with distant metastasis-free survival rates of 88.5% versus 80.2%.

• Benefits were reported across most subgroups, supporting broader biologic credibility for individualized neoantigen targeting.

• Overall survival has not yet separated significantly: interim OS hazard ratio was 0.77 and was not statistically significant.

• Safety will stay in focus: treatment-related discontinuations were higher with the combination than pembrolizumab alone (14% vs 8.7%), while grade 3-5 treatment-related adverse events were similar (14.2% vs 13.4%).

The Financials

• The readout landed at the upper end of investor expectations, with analysts previously signaling that roughly 40% risk reduction would be a key benchmark.

• Even so, Moderna shares fell more than 17% after the detailed data appeared ahead of schedule, reportedly via a third-party leak; Merck shares slipped nearly 2%.

• Barclays analysts have projected about $3 billion in melanoma sales for intismeran by 2035.

What They're Saying

• Lead author Georgina Long called the result “the first Phase III study to show that a treatment built from the unique ‘fingerprint’ of a patient’s own tumour can reduce the risk of recurrence or death from cancer.”

• BMO said the relative reduction in recurrence/death is clinically meaningful and argued the selloff likely reflected inflated expectations rather than weak efficacy.

• UBS described the dataset as overall strong and said it increases confidence in upcoming studies in kidney and bladder cancers.

What's Next

• Clinicians will want longer follow-up to determine whether recurrence-free survival gains convert into a statistically significant overall survival benefit.

• The program is being tested across six tumor types, with Phase II/III readouts in renal, bladder and non-small-cell lung cancer possible before the end of 2027.

• For drug discovery, the key question now is whether this individualized mRNA manufacturing model can scale operationally and reproduce benefit beyond melanoma.

Reference: Three-Year Update of a Randomized Phase IIb Study of the Individualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus Pembrolizumab Versus Pembrolizumab in Resected Melanoma